Chronic Spinal Cord Injury, Spinal Cord Injuries, Subacute Spinal Cord Injury
Conditions
Keywords
Spinal Cord Injury
Brief summary
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects
Detailed description
To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures. NOTE: Enrollment of the chronic cohort has been completed; approximately 20 individuals will be enrolled in the subacute group. For more information about the trial please visit www.connectscistudy.com.
Interventions
DRUGNVG-291
A once daily injection
Sponsors
NervGen Pharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Randomized, Double-Blind, Placebo-Controlled
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
A subject must provide written informed consent in accordance with local regulations prior to initiation of any study-specific activities/procedures. A legally authorized representative (LAR) may be used to assist in signing the informed consent. Cervical SCI resulting from acute physical trauma. Males and females Age 18 - 75 years, inclusive. Cervical SCI, incomplete, with a neurological level of injury being at C7 or higher. Had incomplete cervical SCI within the period from 1 year to 10 years inclusive (Chronic cohort 1) OR within 20 days to 90 days inclusive (Subacute cohort 2) at time of randomization. Must be able to volitionally initiate at least one step on one leg (without body weight support). (Cohort 1 only) Must have a Walking Index for Spinal Cord Injury II (WISCI II) score as follows: 1. For Chronic cohort 1: Less than or equal to Level 14. 2. For Subacute cohort 2: Less than or equal to Level 10. GRASSP/hand grip strength Prehension Ability score For Chronic cohort 1: i. Must have a score of at least 2 on at least one of the Prehension Ability grasp patterns of the GRASSP assessment in at least one upper extremity. ii. Must have no more than one Prehension Ability grasp patterns score = 4 in the upper extremity satisfying criterion i For Subacute cohort 2: i. Must have some voluntary (nonzero) force measured by grip dynamometry in at least one upper extremity. ii. Must have no more than one Prehension Ability grasp patterns score = 3 in at least one upper extremity. iii. Must not have a Prehension Ability grasp patterns score = 4 in the upper extremity satisfying criterion. Presence of Motor Evoked Potentials (MEPs): 1. In two specific target muscle groups (Cohort 1) 2. In one specific target muscle group (Cohort 2) Must be fluent in English. Subjects must be willing and able to comply with scheduled visits, all sample collections, and other trial procedures.
Exclusion criteria
Nontraumatic SCI (e.g., due to infection, ischemia, metabolic abnormality, congenital abnormality, malignancy, radiation injury, surgical complications, or other disease process). Spinal cord injury due to gunshot wound or penetrating injury. Two or more (noncontiguous) spinal cord lesions. MRI or CT evidence of anatomically complete spinal cord transection. Any form of ventilatory dependence. Any condition that precludes adequate clinical assessment of all four extremities, such as contracture, peripheral nerve injury, amputation. History of uncontrolled seizures or any seizure within the last 6 months (Cohort 1). History of uncontrolled seizures, or any seizure occurring 1 week or more after the SCI (Cohort 2) Metal implant in the head that is likely to interfere with MRI analysis. Pregnant or breast feeding. Any neurological condition that is considered to interfere with performance or likly confound assessment, such as multiple sclerosis, stroke, or progressive syringomyelia. History of substance abuse within 12 months prior to screening, based on medical records or self-report. Evidence of spinal instability or persistent spinal stenosis and/or compression related to initial trauma. Prior treatment with cell therapy delivered into the CNS (intrathecal or intraparenchymal). Severe neuropathic pain inadequately controlled by medication. Body mass index (BMI) \> 40 (body weight in kilograms divided by height in meters squared). Received botulinum toxin injection(s) in an upper or lower extremity muscle in the prior 6 months. Received 4-aminopyridine within 7 days of first dose.. Prior treatment with a protein tyrosine phosphatase sigma (PTPσ) mimetic peptide. Intrathecal opioid use. Currently participating in an interventional clinical trial. Received a non-permitted medication within 5.5 half-lives or 7 days, whichever is longer, prior to randomization Receiving any treatment intended to enhance neuroplasticity (e.g., electrical stimulation, acute intermittent hypoxia) at the time of consent to participate in this study or within 4 weeks of randomization, whichever is longer. Any implanted internal spinal cord stimulator. Currently receiving neuromuscular stimulation. Currently receiving vagal or phrenic nerve stimulation. Chronic cohort 1 only: Any contraindication to undergo baseline and on study MRIs such as: 1. History of a cardiac pacemaker or pacemaker wires, OR 2. Ferromagnetic metallic particles in the body, OR 3. Baclofen pump, OR 4. Vascular clips in the head, OR 5. Prosthetic heart valves, OR 6. Severe claustrophobia impeding ability to participate in an imaging study. Malignancy within 5 years prior to screening, except for non-melanoma skin cancers or cervical or breast ductal carcinoma in situ. History of medically significant hepatic disease or evidence of impaired liver function based on initial laboratory testing Severe renal insufficiency, as defined by eGFR \< 30 mL/min/1.73m2. Any disease, concomitant injury, such as significant traumatic brain injury, or other condition that could interfere with the performance or interpretation of the protocol specified assessments, in the opinion of the investigator. Any other social or medical condition (e.g., uncontrolled diabetes, unstable hypertension) which, in the opinion of the investigator, would make the subject unsuitable for study participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Electrophysiological | 12 weeks | MEP amplitudes (corticospinal contribution) in key target muscle groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 10mWT time | 12 weeks | Walking speed |
| 9-HPT time | 12 weeks | Upper extremity dexterity |
| Dynamometry testing (pinch grip, Chronic cohort 1; hand grip, Subacute cohort 2) | 12 weeks | Recorded force |
| Graded and Redefined Assessment of Strength, Sensibility, and Prehension Test | 12 weeks | Hand function Max Score 116 points |
| Lower extremity motor score (LEMS) | 12 weeks | Lower extremity Max Score 50 points |
| Upper extremity motor score (UEMS) | 12 weeks | Upper extremity Max Score 50 points |
| Incidences of Treatment Emergent Adverse Events (Safety and Tolerability) | 16 Weeks | incidences of treatment emergent adverse events |
| Plasma Concentration of Study Drug | 12 Weeks | initial and steady state predose and peak plasma drug concentrations |
Countries
United States
Contacts
STUDY_DIRECTORRandall Kaye, M.D.
NervGen Pharma
Outcome results
None listed